CALR and neoplasm: Platinum-based chemotherapy can enhance host antitumour immune responses in several ways, e.g., inducing immunogenic cell damage (ICD), increasing the activity of tumour-killing immune cells, enhancing the sensitivity of tumour cells to immune checkpoint inhibitors [110], and increasing calreticulin and major histocompatibility complex (MHC I) expression in vivo [111].